SCHEMBL3523124

SCHEMBL3523124

COC(=O)c1c(OC)c(Br)cc2nc(Cl)cnc12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.39
KDM4E B2RXH2 2/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
CSNK2A1 P68400 1/20 0.36
HSD17B10 Q99714 1/20 0.35
MAPT P10636 3/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
NQO2 P16083 1/20 0.34
PTPN1 P18031 1/20 0.33
HPGD P15428 1/20 0.33
ALDH1A1 P00352 2/20 0.33
PSMD14 O00487 1/20 0.32
LMNA P02545 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE1C Q14123 1/20 0.32
TPMT P51580 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3521595 0.80 MAPT (0.37) POLBTSHRHTTHSD17B10MAPT
SCHEMBL18739743 0.77 CSNK2A1 (0.45) POLBKDM4ETSHRHTTCSNK2A1
SCHEMBL3521833 0.77 PTK2 (0.39) KDM4EPTPN1
SCHEMBL3523225 0.77 MAPT (0.45) POLBKDM4ETSHRHTTHSD17B10
SCHEMBL3521139 0.77 TSHR (0.38) TSHRMAPTHPGDALDH1A1LMNA
SCHEMBL3518253 0.76 PDGFRB (0.39) POLBL3MBTL1HPGD
SCHEMBL3521378 0.76 PDGFRB (0.37) KDM4EPTPN1
SCHEMBL3521337 0.76 MEN1 (0.47) KDM4ETSHRHTTHSD17B10MAPT
SCHEMBL3517983 0.76 L3MBTL1 (0.34) POLBKDM4ETSHRHTTHSD17B10
SCHEMBL3517937 0.75 TSHR (0.37) POLBKDM4ETSHRHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 POLB 1207/4885KDM4E 176/4885TSHR 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.